Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
NCT ID: NCT02591277
Last Updated: 2019-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3294 participants
OBSERVATIONAL
2015-11-30
2017-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection
NCT01975675
Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
NCT02759861
Hepatitis C Virus(HCV) Heart and Lung Study
NCT02858180
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
NCT02629172
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
NCT02738333
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Harvoni
Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
Harvoni
Harvoni (90/400 mg) FDC tablet administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Harvoni
Harvoni (90/400 mg) FDC tablet administered orally once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are prescribed Harvoni
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ageo-shi, , Japan
Akita, , Japan
Amagasaki-shi, , Japan
Aomori, , Japan
Arao-shi, , Japan
Asahi-shi, , Japan
Asahikawa-shi, , Japan
Asakura-shi, , Japan
Bunkyō City, , Japan
Chiba, , Japan
Chichibu-shi, , Japan
Chuo-shi, , Japan
Fujioka-shi, , Japan
Fukui-shi, , Japan
Fukuoka, , Japan
Gifu, , Japan
Hakodate-shi, , Japan
Hamamatsu, , Japan
Handa-shi, , Japan
Hashima-shi, , Japan
Hatsukaichi-shi, , Japan
Higashiibaraki-gun, , Japan
Hirosaki-shi, , Japan
Hiroshima, , Japan
Hitachi-shi, , Japan
Hukui-shi, , Japan
Ichikawa-shi, , Japan
Iizuka-shi, , Japan
Ikeda-shi, , Japan
Inashiki-gun, , Japan
Inzai-shi, , Japan
Iruma-gun, , Japan
Ise-shi, , Japan
Iwaki, , Japan
Izumo-shi, , Japan
Izunokuni-shi, , Japan
Kagoshima, , Japan
Kamogawa-shi, , Japan
Kanazawa, , Japan
Karatsu-shi, , Japan
Kashihara-shi, , Japan
Kashiwa-shi, , Japan
Kasukabe-shi, , Japan
Kawagoe-shi, , Japan
Kawaguchi-shi, , Japan
Kawasaki-shi, , Japan
Kirishima-shi, , Japan
Kitakyushu-shi, , Japan
Kitamoto-shi, , Japan
Kobe, , Japan
Kodaira-shi, , Japan
Kofu, , Japan
Komae-shi, , Japan
Komaki-shi, , Japan
Koriyama-shi, , Japan
Koshigaya-shi, , Japan
Kōtoku, , Japan
Kuga-gun, , Japan
Kuki-shi, , Japan
Kumamoto, , Japan
Kurashiki-shi, , Japan
Kure-shi, , Japan
Kurume-shi, , Japan
Kyoto, , Japan
Maebashi, , Japan
Matsumoto-shi, , Japan
Matsuyama, , Japan
Minatoku, , Japan
Miyazaki, , Japan
Moriguchi-shi, , Japan
Morioka, , Japan
Nagakute-shi, , Japan
Nagasaki, , Japan
Nagoya, , Japan
Nakagami-gun, , Japan
Nerima-ku, , Japan
Niigata, , Japan
Nishinomiya-shi, , Japan
Noshiro, , Japan
Obihiro-shi, , Japan
Ofukeshi, , Japan
Okayama, , Japan
Osaka, , Japan
Osakasayama-shi, , Japan
Oume-shi, , Japan
Ōita, , Japan
Ōmihachiman, , Japan
Ōta-ku, , Japan
Ōtsu, , Japan
Saga, , Japan
Saitama-shi, , Japan
Sakaishi, , Japan
Sano-shi, , Japan
Sapporo, , Japan
Sasebo-Shi, , Japan
Sendai, , Japan
Shimonoseki-shi, , Japan
Shimotsuga-gun, , Japan
Shimotsuke-shi, , Japan
Shinagawa-ku, , Japan
Shinjuku-ku, , Japan
Shirakawa-shi, , Japan
Shizuoka, , Japan
Shunan-shi, , Japan
Sumida-ku, , Japan
Tagawa-shi, , Japan
Takamatsu, , Japan
Takasaki-shi, , Japan
Toda-shi, , Japan
Tokorozawa-shi, , Japan
Tokushima, , Japan
Tonami-shi, , Japan
Toyama, , Japan
Toyoake-shi, , Japan
Ureshino-shi, , Japan
Utsunomiya, , Japan
Wakayama, , Japan
Yachiyo-shi, , Japan
Yamagata, , Japan
Yanagawa-shi, , Japan
Yatsushiro-shi, , Japan
Yokkaichi-shi, , Japan
Yokohama, , Japan
Yonago-shi, , Japan
Yoshida-gun, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mizokami M, Liu LJ, Fujiyama N, Littman M, Yuan J, Sekiya T, Hedskog C, Ng LJ. Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. J Viral Hepat. 2021 Jan;28(1):129-141. doi: 10.1111/jvh.13395. Epub 2020 Sep 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS-US-337-1498
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.